Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
C105 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| C105 | DRUG | - |
Inclusion Criteria: * Males/females at least 18 years old and \< 65 years old, capable of understanding and complying with the protocol, including speaking and writing fluent English and having at least a 9th grade education * Clinically definite diagnosis per McDonald criteria of Multiple Sclerosi...
C105 is an investigational small molecule being studied for the treatment of cognitive dysfunction in persons with multiple sclerosis. It is being developed by Cognition Therapeutics, Inc. for the neurology therapeutic area, specifically targeting cognition disorders. The drug is currently in Phase 2 clinical development.
C105 is a small molecule designed to address cognitive dysfunction. While its specific molecular target is not disclosed, it is being investigated for its effects on cognitive function in patients with multiple sclerosis. The drug is being developed by Cognition Therapeutics, Inc. and is currently in Phase 2 clinical trials.
C105 is being developed by Cognition Therapeutics, Inc., a biopharmaceutical company listed on the stock exchange under the ticker CGTX. The company is focused on developing small molecule therapeutics for neurological conditions, with C105 being investigated for cognitive dysfunction in multiple sclerosis.
C105 is currently in Phase 2 clinical development. It has completed one Phase 2 clinical trial, which was a randomized, double-blind study involving 150 participants. The drug is investigational and has not yet been approved by regulatory authorities.
C105 has been studied in a Phase 2 clinical trial with the identifier NCT00529581, titled "A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis." This completed trial enrolled 150 participants in the United States, with a minimum age of 18 years, and included both male and female participants.
C105 is the primary name used for this investigational drug. No alternative names have been reported for this compound. It is being developed by Cognition Therapeutics, Inc. under the ticker CGTX for the treatment of cognitive dysfunction in multiple sclerosis.